Selective cyclooxygenase-2 inhibition suppresses basic fibroblast growth factor expression in human esophageal adenocarcinoma

Molecular Carcinogenesis

Volumn 46, Issue 12, 2007, Pages 971-980

  Baguma Nibasheka, Mark ^a   Barclay, Christie ^a   Li, Audrey W ^a   Geldenhuys, Laurette ^a   Porter, Geoffrey A ^a   Blay, Jonathan ^a   Casson, Alan G ^a,b   Murphy, Paul R ^a  

^a DALHOUSIE UNIVERSITY   (Canada)

^b UNIVERSITY OF SASKATCHEWAN   (Canada)

Author keywords

Anti FGF; COX 2 inhibitor; Esophageal adenocarcinoma; FGF 2

Indexed keywords

CYCLOOXYGENASE 2; FIBROBLAST GROWTH FACTOR; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE;

ADULT; AGED; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL CYCLE PROGRESSION; CELL GROWTH; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG INHIBITION; ESOPHAGEAL ADENOCARCINOMA; FEMALE; HUMAN; HUMAN CELL; IMMUNOREACTIVITY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA TRANSCRIPTION;

ADENOCARCINOMA; AGED; APOPTOSIS; BLOTTING, WESTERN; CELL CYCLE; CELL PROLIFERATION; CYCLOOXYGENASE 2; CYCLOOXYGENASE INHIBITORS; ESOPHAGEAL NEOPLASMS; FEMALE; FIBROBLAST GROWTH FACTOR 2; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NITROBENZENES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SULFONAMIDES; TUMOR CELLS, CULTURED;

EID: 36849094930     PISSN: 08991987     EISSN: 10982744     Source Type: Journal    
DOI: 10.1002/mc.20339     Document Type: Article

References (56)

1. Blot WJ, McLaughlin JK. The changing epidemiology of esophageal cancer. Semin Oncol 1999;26:2-8.
2. Botterweck AA, Schouten LJ, Volovics A, Dorant E, van Den Brandt PA. Trends in incidence of adenocarcinoma of the oesophagus and gastric cardia in ten European countries. Int J Epidemiol 2000;29:645-654.
3. Spechler SJ. Clinical practice. Barrett's Esophagus. N Engl J Med 2002;346:836-842.
4. McManus DT, Olaru A, Meltzer SJ. Biomarkers of esophageal adenocarcinoma and Barrett's esophagus. Cancer Res 2004;64:1561-1569.
5. Wild CP, Hardie LJ. Reflux, Barrett's oesophagus and adenocarcinoma: Burning questions. Nat Rev 2003;3:676-684.
6. Powers CJ, McLesky SW, Wellstein A. Fibroblast growth factors, their receptors and signaling. Endocr Relat Cancer 2000;7:165-197.
7. Iida S, Katoh O, Tokunaga A, Terada M. Expression of fibroblast growth factor gene family and its receptor gene family in the human upper gastrointestinal tract. Biochem Biophys Res Commun 1994;199:1113-1119.
8. Lord RV, Park JM, Wickramasinghe K, et al. Vascular endothelial growth factor and basic fibroblast growth factor expression in esophageal adenocarcinoma and Barrett esophagus. J Thorac Cardiovasc Surg 2003;125:246-253.
9. Barclay C, Li AW, Geldenhuys L, et al. Basic fibroblast growth factor (FGF-2) overexpression is a risk factor for esophageal cancer recurrence and reduced survival, which is ameliorated bycoexpression of the FGF-2 antisense gene. Clin Cancer Res 2005;11:7683-7691.
10. Jones DA, Carlton DP, McIntyre TM, Zimmerman GA, Prescott SM. Molecular cloning of human prostaglandin endoperoxide synthase type II and demonstration of expression in response to cytokines. J Biol Chem 1993;268:9049-9054.
11. Zimmermann KC, Sarbia M, Weber AA, Borchard F, Gabbert HE, Schror K. Cyclooxygenase-2 expression in human esophageal carcinoma. Cancer Res 1999;59:198-204.
12. Yu HP, Xu SQ, Liu L, et al. Cyclooxygenase-2 expression in squamous dysplasia and squamous cell carcinoma of the esophagus. Cancer Lett 2003;198:193-201.
13. Jiang JG, Tang JB, Chen CL, et al. Expression of cyclooxygenase-2 in human esophageal squamous cell carcinomas. World J Gastroenterol 2004;10:2168-2173.
14. Xi H, Baldus SE, Warnecke-Eberz U, et al. High cyclooxygenase-2 expression following neoadjuvant radiochemotherapy is associated with minor histopathologic response and poor prognosis in esophageal cancer. Clin Cancer Res 2005;11:8341-8347.
15. Abdalla EK, Pisters PW. Staging and preoperative evaluation of upper gastrointestinal malignancies. Semin Oncol 2004;31:513-529.
16. Abdalla SI, Sanderson IR, Fitzgerald RC. Effect of inflammation on cyclooxygenase (COX)-2 expression in benign and malignant oesophageal cells. Carcinogenesis 2005;26:1627-1633.
17. Li Y, Wo JM, Ray MB, et al. Cyclooxygenase-2 and epithelial growth factor receptor up-regulation during progression of Barrett's esophagus to adenocarcinoma. World J Gastroenterol 2006;12:928-934.
18. Oyama K, Fujimura T, Ninomiya I, et al. A COX-2 inhibitor prevents the esophageal inflammation-metaplasia-adenocarcinoma sequence in rats. Carcinogenesis 2005;26:565-570.
19. Wang D, Dubois RN. Prostaglandins and cancer. Gut 2006;55:115-122.
20. Piazuelo E, Jimenez P, Lanas A. COX-2 inhibition in esophagitis, Barrett's esophagus and esophageal cancer. Curr Pharm Des 2003;9:2267-2280.
21. Souza RF, Shewmake K, Beer DG, Cryer B, Spechler SJ. Selective inhibition of cyclooxygenase-2 suppresses growth and induces apoptosis in human esophageal adenocarcinoma cells. Cancer Res 2000;60:5767-5772.
22. Vona-Davis L, Riggs DR, Jackson BJ, McFadden DW. Antiproliferative and apoptotic effects of rofecoxib on esophageal cancer in vitro(1). J Surg Res 2004;119:143-148.
23. Yu HP, Shi LY, Lu WH, Su YH, Li YY, Xu SQ. Expression of cyclooxygenase-2 (COX-2) in human esophageal cancer and in vitro inhibition by a specific COX-2 inhibitor, NS-398. J Gastroenterol Hepatol 2004;19:638-642.
24. Buttar NS, Wang KK, Anderson MA, et al. The effect of selective cyclooxygenase-2 inhibition in Barrett's esophagus epithelium: An in vitro study. J Natl Cancer Inst 2002;94:422-429.
25. Sawaoka H, Tsuji S, Tsujii M, et al. Cyclooxygenase inhibitors suppress angiogenesis and reduce tumor growth in vivo. Lab Invest 1999;79:1469-1477.
26. Sanchez-Fidalgo S, Martin-Lacave I, Illanes M, Motilva V. Angiogenesis, cell proliferation and apoptosis in gastric ulcer healing. Effect of a selective cox-2 inhibitor. Eur J Pharmacol 2004;505:187-194.
27. Guo JS, Cho CH, Lam Liu ES, Choy HT, Wang JY, Leung Koo MW. Antiangiogenic effect of a highly selective cyclooxygenase-2 inhibitor on gastric ulcer healing in rats. Toxicol Appl Pharmacol 2002;183:41-45.
28. Masferrer JL, Leahy KM, Koki AT, et al. Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. Cancer Res 2000;60:1306-1311.
29. Yoshida S, Amano H, Hayashi I, et al. COX-2A/EGF-dependent facilitation of tumor-associated angiogenesis and tumor growth in vivo. Lab Invest 2003;83:1385-1394.
30. Li AW, Too CKL, Knee R, Wilkinson M, Murphy PR. FGF-2 antisense RNA encodes a nuclear protein with MutT-like antimutator activity. Mol Cell Endocrinol 1997;133:177-182.
31. Li AW, Too CKL, Murphy PR. The basic fibroblast growth factor (FGF-2) antisense RNA (GFG) is translated into a MutT-related protein in vivo. Biochem Biophys Res Commun 1996;223:19-23.
32. Baguma-Nibasheka M, Li AW, Osman MS, et al. Coexpression and regulation of the FGF-2 and FGF antisense genes in leukemic cells. Leuk Res 2005;29:423-433.
33. Kato M, Nishida S, Kitasato H, Sakata N, Kawai S. Cyclooxygenase-1 and cyclooxygenase-2 selectivity of non-steroidal anti-inflammatory drugs: Investigation using human peripheral monocytes. J Pharm Pharmacol 2001;53:1679-1685.
34. Cryer B, Feldman M. Cyclooxygenase-1 and cyclooxygenase-2 selectivity of widely used nonsteroidal anti-inflammatory drugs. Am J Med 1998;104:413-421.
35. Souza RF, Shewmake K, Pearson S, et al. Acid increases proliferation via ERK and p38 MAPK-mediated increases in cyclooxygenase-2 in Barrett's adenocarcinoma cells. Am J Physiol Gastrointest Liver Physiol 2004;287:G743-G748.
36. Kaur BS, Khamnehei N, Iravani M, Namburu SS, Lin O, Triadafilopoulos G. Rofecoxib inhibits cyclooxygenase 2 expression and activity and reduces cell proliferation in Barrett's esophagus. Gastroenterology 2002;123:60-67.
37. Kase S, Osaki M, Honjo S, et al. A selective cyclooxygenase-2 inhibitor, NS398, inhibits cell growth and induces cell cycle arrest in the G2/M phase in human esophageal squamous cell carcinoma cells. J Exp Clin Cancer Res 2004;23:301-307.
38. Gallo O, Franchi A, Magnelli L, et al. Cyclooxygenase-2 pathway correlates with VEGF expression in head and neck cancer. Implications for tumor angiogenesis and metastasis. Neoplasia 2001;3:53-61.
39. Wilson KT. Angiogenic markers, neovascularization and malignant deformation of Barrett's esophagus. Dis Esophagus 2002;15:16-21.
40. Sheng H, Shao J, Morrow JD, Beauchamp RD, DuBois RN. Modulation of apoptosis and Bcl-2 expression by prostaglandin E2 in human colon cancer cells. Cancer Res 1998;58:362-366.
41. Sheng GG, Shao J, Sheng H, et al. A selective cyclooxygenase 2 inhibitor suppresses the growth of H-ras-transformed rat intestinal epithelial cells. Gastroenterology 1997;113:1883-1891.
42. Kase S, Osaki M, Honjo S, et al. Expression of cyclooxygenase-2 is correlated with high intratumoral microvessel density and low apoptotic index in human esophageal squamous cell carcinomas. Virch Arch 2003;442:129-135.
43. Ashby B. Co-expression of prostaglandin receptors with opposite effects: A model for homeostattc control of autocrine and paracrine signaling. Biochem Pharmacol 1998;55:239-244.
44. Shibata F, Baird A, Florkiewicz RZ. Functional characterization of the human basic fibroblast growth factor gene promoter. Growth Factors 1991;4:277-287.
45. Faris M, Ensoli B, Kokot N, Nel AE. Inflammatory cytokines induce the expression of basic fibroblast growth factor (bFGF) isoforms required for the growth of Kaposi's sarcoma and endothelial cells through the activation of AP-1 response elements in the bFGF promoter. AIDS 1998;12:19-27.
46. Murphy PR, Sato Y, Sato R, Friesen HG. Regulation of multiple basic FGF mRNA transcripts by protein kinase C activators. Mol Endocrinol 1988;2:1196-1201.
47. Moffett J, Kratz E, Myers J, Stachowiak EK, Florkiewicz RZ, Stachowiak MK. Transcriptional regulation of fibroblast growth factor-2 expression in human astrocytes: Implications for cell plasticity. Mol Biol Cell 1998;9:2269-2285.
48. Piazuelo E, Jimenez P, Strunk M, et al. Effects of selective PGE(2) receptor antagonists in esophageal adenocarcinoma cells derived from Barrett's esophagus. Prostaglandins Other Lipid Mediat 2006;81:150-161.
49. Cheng T, Cao W, Wen R, Steinberg RH, LaVail MM. Prostaglandin E2 induces vascular endothelial growth factor and basic fibroblast growth factor mRNA expression in cultured rat Muller cells. Invest Ophthalmol Visual Sci 1998;39:581-591.
50. Morris CD, Armstrong GR, Bigley G, Green H, Attwood SE. Cyclooxygenase-2 expression in the Barrett's metaplasia-dysplasia-adenocarcinoma sequence. Am J Gastroenterol 2001;96:990-996.
51. van der Woude CJ, Jansen PL, Tiebosch AT, et al. Expression of apoptosis-related proteins in Barrett's metaplasia-dysplasia-carcinoma sequence: A switch to a more resistant phenotype. Hum Pathol 2002;33:686-692.
52. Lagorce C, Paraf F, Vidaud D, et al. Cyclooxygenase-2 is expressed frequently and early in Barrett's oesophagus and associated adenocarcinoma. Histopathology 2003;42:457-465.
53. Buskens CJ, Sivula A, van Rees BP, et al. Comparison of cyclooxygenase 2 expression in adenocarcinomas of the gastric cardia and distal oesophagus. Gut 2003;52:1678-1683.
54. Heeren P, Plukker J, van Dullemen H, Nap R, Hollema H. Prognostic role of cyclooxygenase-2 expression in esophageal carcinoma. Cancer Lett 2005;225:283-289.
55. von Rahden BH, Stein HJ, Puhringer F, et al. Coexpression of cyclooxygenases (COX-1, COX-2) and vascular endothelial growth factors (VEGF-A, VEGF-C) in esophageal adenocarcinoma. Cancer Res 2005;65:5038-5044.
56. Brabender J, Marjoram P, Lord RV, et al. The molecular signature of normal squamous esophageal epithelium identifies the presence of a field effect and can discriminate between patients with Barrett's esophagus and patients with Barrett's-associated adenocarcinoma. Cancer Epidemiol Biomarkers Prev 2005;14:2113-2117.